File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation

TitleA prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation
Authors
Issue Date2005
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2005, v. 20 n. 11, p. 3062-3066 How to Cite?
AbstractBackground: Sublingual misoprostol has been shown to be effective in medical abortion. A prospective double-blinded placebo-controlled trial was done to compare the efficacy and side-effects of sublingual to oral misoprostol when used with mifepristone for medical abortion from 12 to 20 weeks gestation. Methods: A total of 120 women at 12-20 weeks of gestation were randomized to receive 200 mg oral mifepristone followed by either sublingual or oral misoprostol 400 mg every 3 h for a maximum of five doses 36-48 h later. The course of misoprostol was repeated if the woman did not abort within 24 h. Results: There was no significant difference (P = 0.43) in the success rate at 24 h [relative risk = 1.075; 95% confidence interval (CI): 0.94-1.19]. Abortion occurred in 91.4% in the sublingual group (95% CI: 81.0-96.7%) as compared to 85.0% (95% CI: 73.7-92.1%) in the oral group. The median induction-to-abortion interval was significantly shorter (P = 0.009) in the sublingual group (5.5 h) as compared to the oral group (7.5 h). The incidence of fever was higher in the sublingual group (P < 0.0001). The incidences of other side-effects were similar. Conclusion: Sublingual misoprostol, when combined with mifepristone, is effective for medical abortion in the second trimester. The induction-to-abortion interval is shorter when sublingual misoprostol is used when compared to oral misoprostol. © The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173295
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, OSen_US
dc.contributor.authorChan, CCWen_US
dc.contributor.authorKan, ASYen_US
dc.contributor.authorHo, PCen_US
dc.date.accessioned2012-10-30T06:29:09Z-
dc.date.available2012-10-30T06:29:09Z-
dc.date.issued2005en_US
dc.identifier.citationHuman Reproduction, 2005, v. 20 n. 11, p. 3062-3066en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/173295-
dc.description.abstractBackground: Sublingual misoprostol has been shown to be effective in medical abortion. A prospective double-blinded placebo-controlled trial was done to compare the efficacy and side-effects of sublingual to oral misoprostol when used with mifepristone for medical abortion from 12 to 20 weeks gestation. Methods: A total of 120 women at 12-20 weeks of gestation were randomized to receive 200 mg oral mifepristone followed by either sublingual or oral misoprostol 400 mg every 3 h for a maximum of five doses 36-48 h later. The course of misoprostol was repeated if the woman did not abort within 24 h. Results: There was no significant difference (P = 0.43) in the success rate at 24 h [relative risk = 1.075; 95% confidence interval (CI): 0.94-1.19]. Abortion occurred in 91.4% in the sublingual group (95% CI: 81.0-96.7%) as compared to 85.0% (95% CI: 73.7-92.1%) in the oral group. The median induction-to-abortion interval was significantly shorter (P = 0.009) in the sublingual group (5.5 h) as compared to the oral group (7.5 h). The incidence of fever was higher in the sublingual group (P < 0.0001). The incidences of other side-effects were similar. Conclusion: Sublingual misoprostol, when combined with mifepristone, is effective for medical abortion in the second trimester. The induction-to-abortion interval is shorter when sublingual misoprostol is used when compared to oral misoprostol. © The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.rightsHuman Reproduction. Copyright © Oxford University Press.-
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosageen_US
dc.subject.meshAbortion, Induced - Methodsen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdministration, Sublingualen_US
dc.subject.meshAdulten_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosageen_US
dc.subject.meshMisoprostol - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Trimester, Seconden_US
dc.subject.meshProspective Studiesen_US
dc.titleA prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestationen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1093/humrep/dei196en_US
dc.identifier.pmid16037110-
dc.identifier.scopuseid_2-s2.0-27944495262en_US
dc.identifier.hkuros119039-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27944495262&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume20en_US
dc.identifier.issue11en_US
dc.identifier.spage3062en_US
dc.identifier.epage3066en_US
dc.identifier.isiWOS:000233045700014-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTang, OS=7006723402en_US
dc.identifier.scopusauthoridChan, CCW=26643394500en_US
dc.identifier.scopusauthoridKan, ASY=8574836200en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.citeulike368728-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats